Zynerba Pharmaceuticals Performance
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
The firm maintains a market beta of 1.05, which attests to a somewhat significant risk relative to the market. Zynerba Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Zynerba Pharmaceuticals is expected to follow. Zynerba Pharmaceuticals right now maintains a risk of 0.0%. Please check out Zynerba Pharmaceuticals maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if Zynerba Pharmaceuticals will be following its historical returns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Zynerba Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Zynerba Pharmaceuticals is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 67.8 M | |
| Free Cash Flow | -23.2 M |
Zynerba |
Zynerba Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 36.00 in Zynerba Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 0.00 from holding Zynerba Pharmaceuticals or generate 0.0% return on investment over 90 days. Zynerba Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Zynerba, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Zynerba Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Zynerba Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Zynerba Pharmaceuticals, and traders can use it to determine the average amount a Zynerba Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ZYNE |
Based on monthly moving average Zynerba Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Zynerba Pharmaceuticals by adding Zynerba Pharmaceuticals to a well-diversified portfolio.
Zynerba Pharmaceuticals Fundamentals Growth
Zynerba Stock prices reflect investors' perceptions of the future prospects and financial health of Zynerba Pharmaceuticals, and Zynerba Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Zynerba Stock performance.
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X | |||
| EBITDA | (34.62 M) | |||
| Cash And Equivalents | 62.49 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 334.43 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (23.03 M) | |||
| Earnings Per Share | (0.80) X | |||
| Total Asset | 55.52 M | |||
| Retained Earnings | (274.52 M) | |||
| Current Asset | 43.42 M | |||
| Current Liabilities | 3.94 M | |||
About Zynerba Pharmaceuticals Performance
By analyzing Zynerba Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Zynerba Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Zynerba Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Zynerba Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania. Zynerba Pharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 28 people.Things to note about Zynerba Pharmaceuticals performance evaluation
Checking the ongoing alerts about Zynerba Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Zynerba Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Zynerba Pharmaceuticals is not yet fully synchronised with the market data | |
| Zynerba Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Zynerba Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (35.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zynerba Pharmaceuticals currently holds about 62.49 M in cash with (23.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Zynerba Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Zynerba Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Zynerba Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Zynerba Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Zynerba Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Zynerba Pharmaceuticals' stock. These opinions can provide insight into Zynerba Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |